Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albenatide in Patients with Type 2 Diabetes Inadequately Controlled by Metformin
NCT07057271Phase 3Completed
- Sponsor
- Changshan ConjuChem Biopharmaceutical Research and Development (Hebei) Co., Ltd.
- Start
- May 2021
- Primary completion
- Feb 2023
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of albenatide in type 2 diabetes mellitus (T2DM), sponsored by Changshan ConjuChem Biopharmaceutical Research and Development (Hebei) Co., Ltd.. Started May 2021; status: completed.
02
Drugs
albenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07057271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07057271.